LIRICA is a prospective non-randomized study aimed at exploring the outcome of liver transplantation in selected patients with unresectable iCCA after a downstaging/disease control protocol with standard of care chemotherapy, in terms of overall survival and quality of life. Additionally, the study aims to identify pre-transplant biological markers and clinical factors that can stratify patients with the best post-transplant prognosis. Finally, the study aims to investigate the role of preoperative PET-MR, especially in relation to lymph node locations, by correlating the results with histological examination after iliac lymphadenectomy.

开始日期2024-01-15

申办/合作机构

Azienda Ospedaliera Ospedale Maggiore di Crema

[+1]

NCT06125769 / RecruitingN/A

LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)

LITALHICA is a prospective non-randomized study aimed at exploring the outcome of liver transplantation in selected patients with unresectable perihilar cholangiocarcinoma (pCCA) after treatment with standard of care chemotherapy, in terms of overall survival and quality of life. Additionally, the study aims to identify pre-transplant biological markers and clinical factors that can stratify patients with the best post-transplant prognosis. Finally, the study aims to investigate the role of preoperative PET-MRI, especially in relation to lymph node locations, by correlating the results with histological examination after hilar lymphadenectomy.

开始日期2024-01-15

申办/合作机构

Azienda Ospedaliera Ospedale Maggiore di Crema

[+1]

NCT04208854 / Unknown statusN/AIIT

Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC)

Vinorelbine is the first line reference drug in the elderly patient with locally advanced / metastatic non-small-cell lung cancer (NSCLC). The introduction of the oral formulation of vinorelbine has determined a further impulse to its use in 1st line and above all to its use as "metronomic" therapy. Metronomic chemotherapy offers the advantage of increasing the overall dosage of the drug administered, but reducing the side effects or making them more easily manageable; it is practically a question of administering fractionated doses of the drug continuously for long periods (generally up to the progression of unacceptable disease or toxicity). This study collects data on the efficacy and tolerability of oral metronomic vinorelbine in elderly patients with NSCLC, performed as per normal clinical practice.

开始日期2018-04-18

申办/合作机构

Azienda Ospedaliera Ospedale Maggiore di Crema

100 项与 Azienda Ospedaliera Ospedale Maggiore di Crema 相关的临床结果

登录后查看更多信息

0 项与 Azienda Ospedaliera Ospedale Maggiore di Crema 相关的专利（医药）

登录后查看更多信息

103

项与 Azienda Ospedaliera Ospedale Maggiore di Crema 相关的文献（医药）

2020-10-01·Giornale italiano di cardiologia (2006)

[The unmet needs of sudden cardiac death. The role of the wearable cardioverter defibrillator when the risk is transient or uncertain].

Review

作者: Guerra, Federico ; Palmisano, Pietro ; Boriani, Giuseppe ; Zanotto, Gabriele ; Landolina, Maurizio ; Bisignani, Giovanni ; Ricci, Renato Pietro ; Berisso, Massimo Zoni ; De Ponti, Roberto ; Forleo, Giovanni ; Stabile, Giuseppe ; Soldati, Ezio

Sudden cardiac death is defined as a natural death due to termination of cardiac activity associated with loss of consciousness, spontaneous breathing and circulation. Nowadays, the prevention of sudden cardiac death represents a major issue and many areas of uncertainty are not met by current evidences. Among those, reliable tools for risk stratification are still lacking, as well as solution for patients in which the risk of sudden cardiac death is due to a transient or correctable condition.The concept of the wearable cardioverter defibrillator is based on a potential solution for such grey areas. It merges long-term monitoring capabilities, shockable rhythm discrimination and shock delivery without the need for bystander assistance or invasive procedures. The present review aims to summarize current problems in dealing with this insidious condition, and to discuss potential options for patients in whom sudden cardiac death could be prevented more safely and cost-effectively.

2018-03-01·Heart Rhythm1区 · 医学

Pulmonary vein isolation cryoablation for patients with persistent and long-standing persistent atrial fibrillation: Clinical outcomes from the real-world multicenter observational project

1区 · 医学

Article

作者: Manfrin, Massimiliano ; Sciarra, Luigi ; Iacopino, Saverio ; Pieragnoli, Paolo ; Landolina, Maurizio ; Padeletti, Luigi ; Tondo, Claudio ; Fassini, Gaetano ; Curnis, Antonio ; Arena, Giuseppe ; Luzi, Mario ; Molon, Giulio ; Verlato, Roberto ; Allocca, Giuseppe

BACKGROUNDPulmonary vein isolation (PVI) is a cornerstone ablation strategy in the management of patients with atrial fibrillation (AF). Consensus guidelines and statements recommend PVI during the index catheter ablation procedure in patients with paroxysmal and persistent AF.OBJECTIVEThe objective of this analysis was to evaluate patients with persistent and long-standing persistent AF who were treated with the cryoballoon ablation catheter by PVI technique.METHODSConsecutive patients with drug-refractory symptomatic persistent and long-standing persistent AF who underwent cryoballoon catheter ablation by a PVI-only procedure were prospectively included in this single-arm multicenter evaluation. Data on procedural characteristics, safety, and long-term freedom from AF recurrence were analyzed.RESULTSFour hundred eighty-six subjects (mean age 60.8 ± 9.3 years; 389 (80%) men; 434 (89.3%) with persistent AF; 52 (10.7%) with long-standing persistent AF; left atrial diameter 44.6 ± 6.2 mm) underwent cryoballoon ablation in 35 Italian centers. The mean procedure time (skin-to-skin) was 109.9 ± 52.9 minutes, and the mean fluoroscopy time was 29.6 ± 14.5 minutes. Periprocedural complications were observed in 21 subjects (4.3%), and the acute PVI success rate was 97.6% across all patients. Using a 90-day blanking period, the single procedure Kaplan-Meier estimates of AF event-free survival were 63.9% at 12 months and 51.5% at 18 months.CONCLUSIONIn this multicenter evaluation of cryoballoon ablation, the PVI procedure was safe, effective, and efficient with regard to the treatment of patients with persistent and long-standing persistent AF. The reasonable mid-term success rates agree with current clinical studies that establish PVI as a cornerstone index ablation strategy.

2017-03-01·La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine

Percorso di laboratorio raccomandato nella diagnosi, prognosi e follow-up delle gammopatie monoclonali